{"id":"NCT03219216","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-06","primaryCompletion":"2019-03-11","completion":"2019-03-11","firstPosted":"2017-07-17","resultsPosted":"2020-03-17","lastUpdate":"2020-03-17"},"enrollment":100,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493","ABT-530","MAVYRET"]}],"arms":[{"label":"Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks","type":"EXPERIMENTAL"},{"label":"Arm B: GLE/PIB for 12 Weeks","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) for an 8 or 12-week treatment duration in adults in Brazil with chronic hepatitis C virus (HCV) genotype (GT) 1 to GT6 infection, without cirrhosis or with compensated cirrhosis, who were HCV treatment-naïve.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after last dose of study drug (week 20 or 24 depending on treatment regimen)","effectByArm":[{"arm":"All Participants","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":14,"countries":["Brazil"]},"refs":{"pmids":["35174470","32949786"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":100},"commonTop":["HEADACHE","PRURITUS","NAUSEA","FATIGUE"]}}